PD Latest Research

Newsfeed:

  • A Flavonoid-Rich Extract of Mandarin Juice Counteracts 6-OHDA-Induced Oxidative Stress in SH-SY5Y Cells and Modulates Parkinson-Related Genes
    Antioxidants (Basel). 2021 Mar 30;10(4):539. doi: 10.3390/antiox10040539.ABSTRACTParkinson's disease (PD) is a degenerative disorder of the nervous system due to unceasing impairment of dopaminergic neurons situated in the substantia nigra. At present, anti-PD drugs acting on dopamine receptors are mainly symptomatic and have only very limited neuroprotective effects, whereas drugs slowing down neurodegeneration of dopaminergic neurons and deterioration of clinical symptoms ... read more
    Source: PubMedPublished on 2021-04-03By Santa Cirmi
  • Pre-Clinical Neuroprotective Evidences and Plausible Mechanisms of Sulforaphane in Alzheimer’s Disease
    Int J Mol Sci. 2021 Mar 13;22(6):2929. doi: 10.3390/ijms22062929.ABSTRACTSulforaphane, a potent dietary bioactive agent obtainable from cruciferous vegetables, has been extensively studied for its effects in disease prevention and therapy. Sulforaphane potently induces transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2)-mediated expression of detoxification, anti-oxidation, and immune system-modulating enzymes, and possibly acts as an anti-carcinogenic agent. Several clinical trials ... read more
    Source: PubMedPublished on 2021-04-03By Jiyoung Kim
  • Dopamine D3 Receptor Plasticity in Parkinson’s Disease and L-DOPA-Induced Dyskinesia
    Biomedicines. 2021 Mar 19;9(3):314. doi: 10.3390/biomedicines9030314.ABSTRACTParkinson's Disease (PD) is characterized by primary and secondary plasticity that occurs in response to progressive degeneration and long-term L-DOPA treatment. Some of this plasticity contributes to the detrimental side effects associated with chronic L-DOPA treatment, namely L-DOPA-induced dyskinesia (LID). The dopamine D3 receptor (D3R) has emerged as a promising target in LID management as ... read more
    Source: PubMedPublished on 2021-04-03By Kathryn Lanza
  • Deep brain stimulation outcomes in the malignant end of Parkinson’s disease spectrum
    Parkinsonism Relat Disord. 2021 Mar 28;86:5-9. doi: 10.1016/j.parkreldis.2021.03.017. Online ahead of print.ABSTRACTBACKGROUND: Heterogeneity of Parkinson's Disease (PD) phenotype may influence deep brain stimulation (DBS) outcome. However, DBS response in the malignant end of the PD spectrum has been poorly investigated.OBJECTIVE: To evaluate and compare DBS outcomes in malignant and benign PD patients, defined according to motor and non-motor symptom presentation ... read more
    Source: PubMedPublished on 2021-04-03By Carlo Alberto Artusi
  • Pre-Clinical Neuroprotective Evidences and Plausible Mechanisms of Sulforaphane in Alzheimer’s Disease
    Int J Mol Sci. 2021 Mar 13;22(6):2929. doi: 10.3390/ijms22062929.ABSTRACTSulforaphane, a potent dietary bioactive agent obtainable from cruciferous vegetables, has been extensively studied for its effects in disease prevention and therapy. Sulforaphane potently induces transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2)-mediated expression of detoxification, anti-oxidation, and immune system-modulating enzymes, and possibly acts as an anti-carcinogenic agent. Several clinical trials ... read more
    Source: PubMedPublished on 2021-04-03By Jiyoung Kim
  • Docosahexaenoic and Arachidonic Acids as Neuroprotective Nutrients throughout the Life Cycle
    Nutrients. 2021 Mar 18;13(3):986. doi: 10.3390/nu13030986.ABSTRACTThe role of docosahexaenoic acid (DHA) and arachidonic acid (AA) in neurogenesis and brain development throughout the life cycle is fundamental. DHA and AA are long-chain polyunsaturated fatty acids (LCPUFA) vital for many human physiological processes, such as signaling pathways, gene expression, structure and function of membranes, among others. DHA and AA are deposited into ... read more
    Source: PubMedPublished on 2021-04-03By Verónica Sambra
  • Validation of Cognitive Rehabilitation as a Balance Rehabilitation Strategy in Patients with Parkinson’s Disease: Study Protocol for a Randomized Controlled Trial
    Medicina (Kaunas). 2021 Mar 26;57(4):314. doi: 10.3390/medicina57040314.ABSTRACTBackground: Parkinson's disease (PD) is the second most common neurodegenerative disorder. This disease is characterized by motor symptoms, such as bradykinesia, tremor, and rigidity. Although balance impairment is characteristic of advanced stages, it can be present with less intensity since the beginning of the disease. Approximately 60% of PD patients fall once a year ... read more
    Source: PubMedPublished on 2021-04-03By Aida Arroyo-Ferrer
  • Predicting the Severity of Parkinson’s Disease Dementia by Assessing the Neuropsychiatric Symptoms with an SVM Regression Model
    Int J Environ Res Public Health. 2021 Mar 4;18(5):2551. doi: 10.3390/ijerph18052551.ABSTRACTIn this study, we measured the convergence rate using the mean-squared error (MSE) of the standardized neuropsychological test to determine the severity of Parkinson's disease dementia (PDD), which is based on support vector machine (SVM) regression (SVR) and present baseline data in order to develop a model to predict the ... read more
    Source: PubMedPublished on 2021-04-03By Haewon Byeon
  • Quantitative Assessment of Occipital Metabolic and Energetic Changes in Parkinson’s Patients, Using In Vivo (31)P MRS-Based Metabolic Imaging at 7T
    Metabolites. 2021 Mar 1;11(3):145. doi: 10.3390/metabo11030145.ABSTRACTAbnormal energy metabolism associated with mitochondrial dysfunction is thought to be a major contributor to the progression of neurodegenerative diseases such as Parkinson's disease (PD). Recent advancements in the field of magnetic resonance (MR) based metabolic imaging provide state-of-the-art technologies for non-invasively probing cerebral energy metabolism under various brain conditions. In this proof-of-principle clinical study, ... read more
    Source: PubMedPublished on 2021-04-03By Xiao-Hong Zhu
  • Validation of Cognitive Rehabilitation as a Balance Rehabilitation Strategy in Patients with Parkinson’s Disease: Study Protocol for a Randomized Controlled Trial
    Medicina (Kaunas). 2021 Mar 26;57(4):314. doi: 10.3390/medicina57040314.ABSTRACTBackground: Parkinson's disease (PD) is the second most common neurodegenerative disorder. This disease is characterized by motor symptoms, such as bradykinesia, tremor, and rigidity. Although balance impairment is characteristic of advanced stages, it can be present with less intensity since the beginning of the disease. Approximately 60% of PD patients fall once a year ... read more
    Source: PubMedPublished on 2021-04-03By Aida Arroyo-Ferrer
  • Dopamine: The Neuromodulator of Long-Term Synaptic Plasticity, Reward and Movement Control
    Cells. 2021 Mar 26;10(4):735. doi: 10.3390/cells10040735.ABSTRACTDopamine (DA) is a key neurotransmitter involved in multiple physiological functions including motor control, modulation of affective and emotional states, reward mechanisms, reinforcement of behavior, and selected higher cognitive functions. Dysfunction in dopaminergic transmission is recognized as a core alteration in several devastating neurological and psychiatric disorders, including Parkinson's disease (PD), schizophrenia, bipolar disorder, attention ... read more
    Source: PubMedPublished on 2021-04-03By Luisa Speranza
  • Mechanisms of Neurodegeneration in Various Forms of Parkinsonism-Similarities and Differences
    Cells. 2021 Mar 16;10(3):656. doi: 10.3390/cells10030656.ABSTRACTParkinson's disease (PD), dementia with Lewy body (DLB), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and multiple system atrophy (MSA) belong to a group of neurodegenerative diseases called parkinsonian syndromes. They share several clinical, neuropathological and genetic features. Neurodegenerative diseases are characterized by the progressive dysfunction of specific populations of neurons, determining clinical presentation. Neuronal ... read more
    Source: PubMedPublished on 2021-04-03By Dariusz Koziorowski
  • Initial Experience of the Levodopa-Entacapone-Carbidopa Intestinal Gel in Clinical Practice
    J Pers Med. 2021 Mar 31;11(4):254. doi: 10.3390/jpm11040254.ABSTRACTPatients in fluctuating stages of Parkinson's disease (PD) require device-aided treatments. Continuous infusion of levodopa-carbidopa intestinal gel (LCIG) is a well-proven option in clinical practice. We now report the first clinical experience of levodopa-entacapone-carbidopa intestinal gel (LECIG) therapy. An observational study of the first patients to start LECIG in our clinic was performed. ... read more
    Source: PubMedPublished on 2021-04-03By Mezin Öthman
  • Oxidative Stress Conditions Result in Trapping of PHF-Core Tau (297-391) Intermediates
    Cells. 2021 Mar 22;10(3):703. doi: 10.3390/cells10030703.ABSTRACTThe self-assembly of tau into paired helical filaments (PHFs) in neurofibrillary tangles (NFTs) is a significant event in Alzheimer's disease (AD) pathogenesis. Numerous post-translational modifications enhance or inhibit tau assembly into NFTs. Oxidative stress, which accompanies AD, induces multiple post-translational modifications in proteins, including the formation of dityrosine (DiY) cross-links. Previous studies have revealed that ... read more
    Source: PubMedPublished on 2021-04-03By Mahmoud B Maina
  • Initial Experience of the Levodopa-Entacapone-Carbidopa Intestinal Gel in Clinical Practice
    J Pers Med. 2021 Mar 31;11(4):254. doi: 10.3390/jpm11040254.ABSTRACTPatients in fluctuating stages of Parkinson's disease (PD) require device-aided treatments. Continuous infusion of levodopa-carbidopa intestinal gel (LCIG) is a well-proven option in clinical practice. We now report the first clinical experience of levodopa-entacapone-carbidopa intestinal gel (LECIG) therapy. An observational study of the first patients to start LECIG in our clinic was performed. ... read more
    Source: PubMedPublished on 2021-04-03By Mezin Öthman
  • Therapeutic Applications of Botulinum Neurotoxin for Autonomic Symptoms in Parkinson’s Disease: An Updated Review
    Toxins (Basel). 2021 Mar 19;13(3):226. doi: 10.3390/toxins13030226.ABSTRACTParkinson's disease is the most common age-related motoric neurodegenerative disease. In addition to the cardinal motor symptoms of tremor, rigidity, bradykinesia, and postural instability, there are numerous non-motor symptoms as well. Among the non-motor symptoms, autonomic nervous system dysfunction is common. Autonomic symptoms associated with Parkinson's disease include sialorrhea, hyperhidrosis, gastrointestinal dysfunction, and urinary ... read more
    Source: PubMedPublished on 2021-04-03By Steven D Mitchell
  • Cyclin-Dependent Kinases (CDK) and Their Role in Diseases Development-Review
    Int J Mol Sci. 2021 Mar 13;22(6):2935. doi: 10.3390/ijms22062935.ABSTRACTCyclin-dependent kinases (CDKs) are involved in many crucial processes, such as cell cycle and transcription, as well as communication, metabolism, and apoptosis. The kinases are organized in a pathway to ensure that, during cell division, each cell accurately replicates its DNA, and ensure its segregation equally between the two daughter cells. Deregulation ... read more
    Source: PubMedPublished on 2021-04-03By Paweł Łukasik
  • Interactions of COMT and ALDH2 Genetic Polymorphisms on Symptoms of Parkinson’s Disease
    Brain Sci. 2021 Mar 12;11(3):361. doi: 10.3390/brainsci11030361.ABSTRACT(1) Background: Monoamine neurotransmitters play essential roles in the normal functioning of our nervous system. However, the metabolism of monoamine neurotransmitters is accompanied by the production of neurotoxic metabolites, and inefficient removal of the metabolites has been suggested to cause neurodegeneration. (2) Methods: To examine the effect of reduced activity of catechol-O-methyltransferase (COMT) and ... read more
    Source: PubMedPublished on 2021-04-03By Rwei-Ling Yu
  • Life Satisfaction and Adaptation in Persons with Parkinson’s Disease-A Qualitative Study
    Int J Environ Res Public Health. 2021 Mar 23;18(6):3308. doi: 10.3390/ijerph18063308.ABSTRACTPersons with Parkinson's disease (PD) need to adapt to their progressive disability to achieve and maintain a high degree of life satisfaction (LS), but little is known about the meaning of LS and adaptation. This study aimed to gain an in-depth understanding of the meaning of LS and adaptation in ... read more
    Source: PubMedPublished on 2021-04-03By Lina Rosengren
  • Lysosome dysfunction as a cause of neurodegenerative diseases: Lessons from frontotemporal dementia and amyotrophic lateral sclerosis
    Neurobiol Dis. 2021 Mar 31:105360. doi: 10.1016/j.nbd.2021.105360. Online ahead of print.ABSTRACTFrontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) are fatal neurodegenerative disorders that are thought to exist on a clinical and pathological spectrum. FTD and ALS are linked by shared genetic causes (i.e. C9orf72 hexanucleotide repeat expansions) and neuropathology, such as inclusions of ubiquitinated, misfolded proteins (i.e. TAR DNA-binding protein ... read more
    Source: PubMedPublished on 2021-04-03By Jessica Root
  • Assessment of Gastrointestinal Autonomic Dysfunction: Present and Future Perspectives
    J Clin Med. 2021 Mar 31;10(7):1392. doi: 10.3390/jcm10071392.ABSTRACTThe autonomic nervous system delicately regulates the function of several target organs, including the gastrointestinal tract. Thus, nerve lesions or other nerve pathologies may cause autonomic dysfunction (AD). Some of the most common causes of AD are diabetes mellitus and α-synucleinopathies such as Parkinson's disease. Widespread dysmotility throughout the gastrointestinal tract is a ... read more
    Source: PubMedPublished on 2021-04-03By Ditte S Kornum
  • LRRK2 at the Crossroad of Aging and Parkinson’s Disease
    Genes (Basel). 2021 Mar 29;12(4):505. doi: 10.3390/genes12040505.ABSTRACTParkinson's disease (PD) is a heterogeneous neurodegenerative disease characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta and the widespread occurrence of proteinaceous inclusions known as Lewy bodies and Lewy neurites. The etiology of PD is still far from clear, but aging has been considered as the highest risk ... read more
    Source: PubMedPublished on 2021-04-03By Eun-Mi Hur
  • Interactions of COMT and ALDH2 Genetic Polymorphisms on Symptoms of Parkinson’s Disease
    Brain Sci. 2021 Mar 12;11(3):361. doi: 10.3390/brainsci11030361.ABSTRACT(1) Background: Monoamine neurotransmitters play essential roles in the normal functioning of our nervous system. However, the metabolism of monoamine neurotransmitters is accompanied by the production of neurotoxic metabolites, and inefficient removal of the metabolites has been suggested to cause neurodegeneration. (2) Methods: To examine the effect of reduced activity of catechol-O-methyltransferase (COMT) and ... read more
    Source: PubMedPublished on 2021-04-03By Rwei-Ling Yu
  • Disclosing the potential of eleganolone for Parkinson’s disease therapeutics: Neuroprotective and anti-inflammatory activities
    Pharmacol Res. 2021 Mar 31:105589. doi: 10.1016/j.phrs.2021.105589. Online ahead of print.ABSTRACTThe treatment of Parkinson´s disease (PD) has benefited from significant advances resulting from the increasing research efforts focused on new therapeutics. However, the current treatments for PD are mostly symptomatic, alleviating disease symptoms without reversing or retarding disease progression. Thus, it is critical to find new molecules that can result ... read more
    Source: PubMedPublished on 2021-04-03By Joana Silva
  • LRRK2 at the Crossroad of Aging and Parkinson’s Disease
    Genes (Basel). 2021 Mar 29;12(4):505. doi: 10.3390/genes12040505.ABSTRACTParkinson's disease (PD) is a heterogeneous neurodegenerative disease characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta and the widespread occurrence of proteinaceous inclusions known as Lewy bodies and Lewy neurites. The etiology of PD is still far from clear, but aging has been considered as the highest risk ... read more
    Source: PubMedPublished on 2021-04-03By Eun-Mi Hur
1 1,148 1,149 1,150 1,151 1,152 1,538